Co-Diagnostics (CODX) Expected to Announce Quarterly Earnings on Thursday

Co-Diagnostics (NASDAQ:CODX) is projected to announce its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Co-Diagnostics to announce earnings of ($3.00) per share and revenue of $0.1330 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Co-Diagnostics (NASDAQ:CODX) last released its quarterly earnings data on Thursday, May 14th. The company reported ($4.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.75) by ($0.31). Co-Diagnostics had a negative return on equity of 164.92% and a negative net margin of 6,760.63%.The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.13 million.

Co-Diagnostics Price Performance

Shares of CODX stock opened at $1.51 on Thursday. The company has a market capitalization of $5.56 million, a PE ratio of -0.10 and a beta of 2.87. The firm’s 50-day moving average is $3.42 and its two-hundred day moving average is $2.73. Co-Diagnostics has a 12 month low of $1.26 and a 12 month high of $46.50.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wall Street Zen upgraded Co-Diagnostics to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings cut Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $67.50.

Institutional Investors Weigh In On Co-Diagnostics

Several institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC boosted its holdings in Co-Diagnostics by 393.8% during the 3rd quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock valued at $44,000 after acquiring an additional 100,901 shares during the period. Jane Street Group LLC lifted its position in shares of Co-Diagnostics by 314.1% during the second quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock worth $47,000 after purchasing an additional 126,105 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Co-Diagnostics by 40.4% in the fourth quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock valued at $81,000 after purchasing an additional 129,158 shares during the period. Hedge funds and other institutional investors own 14.99% of the company’s stock.

About Co-Diagnostics

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.